Skip to content
Issue price
₹452
Listing price
₹655
+44.91%
Current price
₹666.2
+47.39%
Subscribed
70.3x
Issue size
₹1,841.76 Cr
Listed on
13 May 2024

IPO timeline

  1. Opens
    6 MayMon
  2. Closes
    8 MayWed
  3. Allotment
    9 MayThu
  4. Refunds
    10 MayFri
  5. Demat credit
    10 MayFri
  6. Listing
    13 MayMon

Issue details

Price band
₹430 – ₹452 per share
Issue size
₹1,841.76 Cr
Fresh issue
Not available
Offer for sale
Not available
Issue type
Fresh capital cum OFS
Face value
₹2 per share
Lot size
33 shares
Minimum investment
₹14,916
Listing on
BSE, NSE
Exchange code
INDGN · 544172

This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)133₹14,916
Retail (Max)13429₹1,93,908
S-HNI (Min)14462₹2,08,824
B-HNI (Min)682,244₹10,14,288

Reservation

QIB
2,02,35,170 shares (50.00% of the Offer)
NII
60,70,552 shares (15.00% of the Offer)
Retail
1,41,64,620 shares (35.00% of the Offer)
Employee
2,96,208 shares (0.73% of the Offer)

Allotment status

Registrar: MUFG Intime India Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on MUFG Intime India
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
9 May 2024
Refunds initiated
10 May 2024
Shares credited to demat
10 May 2024
Listing
13 May 2024

Grey market premium (GMP)

Updated 12 May 2024, 12:00 PM IST
Current GMP
₹300
+66.00%
Estimated listing price
₹752
Issue price ₹452
Highest
₹300
12 May
Lowest
₹230
7 May

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
12 May 2024₹300+66.00%₹752
11 May 2024₹270+60.00%₹722
10 May 2024₹270+60.00%₹722
9 May 2024₹270+60.00%₹722
8 May 2024₹270+60.00%₹722
7 May 2024₹230+51.00%₹682
6 May 2024₹240+53.00%₹692
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 10 Nov 2026, 06:44 AM IST
Overall subscription
70.3x
Fully subscribed
  • QIB192.72x
  • NII (HNI)55.91x
  • Retail7.86x
  • Employee6.62x

Financials

Amounts in Rs. Crore
P/E Ratio
33.53
EPS (₹)
13.48
RoNW
18.23%
PAT Margin
12.62%
Debt / Equity
0.30
NAV (₹)
59.86

Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.

Period ended31 Dec 202331 Mar 202331 Mar 202231 Mar 2021
Assets2,518.152,203.871,353.47596.04
Total Income1,969.752,364.101,690.50996.92
Profit After Tax241.90266.10162.82149.41
NET Worth1,327.001,063.72763.90324.51
Reserves and Surplus1,282.651,019.43763.55324.19
Total Borrowing399.33394.3418.2424.76
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Indegene
This IPO
₹1,841.76 Cr33.5318.23%12.62%70.3x+44.91%
Akums Drugs & Pharmaceuticals
Mainboard · listed 6 Aug 2024
₹1,856.74 Cr13580-0.57%0.02%63.44x+6.77%
Symbiotec Pharmalab
Mainboard · listed 1 Sep 2026
₹1,757 Cr56.819.48%12.60%71.26x0.00%
Sagility India
Mainboard · listed 12 Nov 2024
₹2,106.4 Cr61.520.29%11.83%3.2x+3.53%
Entero Healthcare Solutions
Mainboard · listed 16 Feb 2024
₹1,600 Cr129.75-1.86%4.69%1.56x-2.33%
Paras Healthcare
Mainboard · listed 28 Oct 2026
₹1,450 Cr37.7211.83%10.38%2.23x+3.90%
Rubicon Research
Mainboard · listed 16 Oct 2025
₹1,378 Cr46.1329.02%10.37%109.32x+27.84%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

₹724.38 Cr total

How Indegene plans to use the money raised, as stated in the offer document.

  1. Repayment/prepaymentof indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc₹391.34 Cr
  2. Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.₹102.92 Cr
  3. General Corporate Purposes and Inorganic Growth₹230.12 Cr

About Indegene

Indegene Limited was incorporated in India in 1998. It provides digital-led commercialisation services for biopharmaceutical, emerging biotech and medical device companies. Its solutions help with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of products. It combines over two decades of healthcare domain expertise with its technology platforms. As of 31 December 2023 it had 65 active clients, served from six operation hubs and 17 offices across North America, Europe and Asia. Its subsidiary DT Associates offers consulting under the DT Consulting brand. The company has no identifiable promoter. The IPO was Rs 1,841.76 crore, with Rs 760.52 crore of fresh issue and Rs 1,081.24 crore of offer for sale by investors and other shareholders. Rs 391.34 crore was planned for repaying debt of its subsidiary ILSL Holdings and Rs 102.92 crore for capital expenditure.

Strengths

  • Total income rose from Rs 996.92 crore in FY2021 to Rs 2,364.10 crore in FY2023.
  • Profit after tax rose from Rs 149.41 crore in FY2021 to Rs 266.10 crore in FY2023.
  • Profit after tax was Rs 241.90 crore in the nine months to 31 December 2023.
  • The source puts the PAT margin at 12.62% and return on net worth at 18.23%.
  • Rs 391.34 crore of the fresh issue was planned for repaying subsidiary debt.

Risks

  • The pre-issue P/E was 37.78 at the upper band of Rs 452, based on EPS of Rs 11.96.
  • Rs 1,081.24 crore of the Rs 1,841.76 crore issue was offer for sale.
  • Total borrowing rose from Rs 18.24 crore on 31 March 2022 to Rs 399.33 crore on 31 December 2023.
  • It serves only 65 active clients, so the loss of a large client would hurt, and most income is earned abroad in foreign currency.
  • The company has no identifiable promoter, and the post-issue market value at Rs 452 was Rs 10,814.07 crore.

Promoters and shareholding

No Identifiable Promoter

Anchor investors

36 investors · ₹548.81 Cr raised
InvestorShares allottedAmount% of anchor book
SMALLCAP WORLD FUND, INC11,06,094₹50 Cr9.11%
AMERICAN FUNDS INSURANCE SERIES GLOBAL SMALL CAPITALIZATION FUND2,21,331₹10 Cr1.82%
CUSTODY BANK OF JAPAN, LTD. RE: RB AMUNDI INDIA SMALL CAP EQUITY MOTHER FUND8,84,928₹40 Cr7.29%
SBI TECHNOLOGY OPPORTUNITIES FUND4,09,299₹18.5 Cr3.37%
SBI MAGNUM CHILDREN'S BENEFIT FUND33,198₹1.5 Cr0.27%
FIDELITY FUNDS - INDIA FOCUS FUND9,29,181₹42 Cr7.65%
ICICI PRUDENTIAL TECHNOLOGY FUND9,29,181₹42 Cr7.65%
NIPPON LIFE INDIA TRUSTEE LTD- A/C NIPPON INDIA SMALL CAP FUND9,29,181₹42 Cr7.65%
NHIT: GLOBAL EMERGING MARKETS EQUITY TRUST3,09,969₹14.01 Cr2.55%
DESTINATIONS INTERNATIONAL EQUITY FUND, A SERIES OF BRINKER CAPITAL DESTINATIONS TRUST2,87,364₹12.99 Cr2.37%
JUPITER INDIA FUND4,51,044₹20.39 Cr3.72%
THE JUPITER GLOBAL FUND- JUPITER INDIA SELECT1,46,289₹6.61 Cr1.2%
WHITEOAK CAPITAL MID CAP FUND2,95,350₹13.35 Cr2.43%
WHITEOAK CAPITAL MULTI CAP FUND2,13,576₹9.65 Cr1.76%
WHITEOAK CAPITAL ELSS TAX SAVER FUND53,526₹2.42 Cr0.44%
WHITEOAK CAPITAL PHARMA AND HEALTHCARE FUND34,881₹1.58 Cr0.29%
PIONEER INVESTMENT FUND SCHEME II5,97,333₹27 Cr4.92%
DSP SMALL CAP FUND4,42,464₹20 Cr3.64%
EAST BRIDGE CAPITAL MASTER FUND I LTD4,42,464₹20 Cr3.64%
BANDHAN FLEXI CAP FUND3,31,848₹15 Cr2.73%
KOTAK FUNDS - INDIA MIDCAP FUND3,31,848₹15 Cr2.73%
KOTAK ICONIC FUND3,31,848₹15 Cr2.73%
UTI-MID CAP FUND1,74,669₹7.9 Cr1.44%
UTI SMALL CAP FUND87,318₹3.95 Cr0.72%
UTI - HEALTHCARE FUND69,861₹3.16 Cr0.58%
INVESCO TRUSTEE PRIVATE LIMITED - A/C INVESCO INDIA SMALLCAP FUND3,31,848₹15 Cr2.73%
ABU DHABI INVESTMENT AUTHORITY - MONSOON2,76,540₹12.5 Cr2.28%
ADITYA BIRLA SUN LIFE INSURANCE COMPANY LIMITED2,76,540₹12.5 Cr2.28%
EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC- EDELWEISS RECENTLY LISTED IPO FUND1,10,616₹5 Cr0.91%
EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- EDELWEISS AGGRESIVE HYBRID FUND1,10,616₹5 Cr0.91%
EDELWEISS TRUSTEESHIP CO LTD AC- EDELWEISS MF AC- EDELWEISS LARGE CAP FUND55,308₹2.5 Cr0.46%
BAJAJ ALLIANZ LIFE INSURANCE COMPANY LTD.1,92,416₹8.7 Cr1.58%
360 ONE HIGH GROWTH COMPANIES FUND1,92,417₹8.7 Cr1.58%
BARODA BNP PARIBAS FLEXI CAP FUND1,92,416₹8.7 Cr1.58%
BHARTI AXA LIFE INSURANCE COMPANY LTD1,92,416₹8.7 Cr1.58%
COPTHALL MAURITIUS INVESTMENT LIMITED - ODI ACCOUNT1,65,924₹7.5 Cr1.37%

Registrar, lead managers and documents

Indegene IPO: common questions

1.When does the Indegene IPO open and close?

The Indegene IPO opens on 6 May 2024 and closes on 8 May 2024.

2.What is the price band of the Indegene IPO?

The price band is ₹430 – ₹452 per share, with a lot size of 33 shares and a minimum investment of ₹14,916.

3.What is the size of the Indegene IPO?

The issue size is ₹1,841.76 Cr (Fresh capital cum OFS).

4.What is the GMP of the Indegene IPO?

The last reported grey market premium is ₹300 per share as of 12 May 2024, 12:00 PM IST. GMP is unofficial and changes frequently.

5.When is the Indegene IPO allotment?

The basis of allotment is expected on 9 May 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.

6.When will the Indegene IPO list?

The shares listed on 13 May 2024 on BSE, NSE.

7.Who is the lead manager of the Indegene IPO?

The book running lead managers are Kotak Mahindra Capital Company Limited, JP Morgan India Pvt. Ltd, Citigroup Global Markets India Pvt. Ltd, Nomura Financial Advisory & Securities (India) Pvt. Ltd, and the registrar is MUFG Intime India Private Limited.

8.What will the money raised in the Indegene IPO be used for?

As stated in the offer document, the proceeds are for: Repayment/prepaymentof indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc; Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.; General Corporate Purposes and Inorganic Growth.

9.How can my company launch an IPO like Indegene?

Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393